| Drug Type Small molecule drug | 
| Synonyms- | 
| Action inhibitors, antagonists | 
| Mechanism BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors), CRAF inhibitors(C-Raf kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) + [6] | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC21H16ClF3N4O3 | 
| InChIKeyMLDQJTXFUGDVEO-UHFFFAOYSA-N | 
| CAS Registry284461-73-0 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Ovarian Cancer | Phase 1 | - | - | 





